Neogenix Oncology, Inc.  Bankruptcy New Filing Alert: Objection To The To Avoid Alleged Fraudulent Transfers

On June 13, 2014, an objection to the to avoid alleged fraudulent transfers was filed in the bankruptcy case of Neogenix Oncology, Inc.  and its affiliates.

The filing was assigned docket number 437 and is described on the court’s official docket as follows:

Objection filed by James G. Sheehan (related document)[393] Joint Motion of Neogenix Oncology, Inc. and the Official Committee of Equity Interest Holders filed by Creditor Committee Official Committee of Equity Security Holders, Debtor Neogenix Oncology, Inc. Hearing scheduled for 7/1/2014 at 2:00 PM at Courtroom 3-E, Greenbelt – Judge Catliota. (Rybczynski, Mark)

Neogenix Oncology, Inc.  filed for bankruptcy protection, or had an involuntary bankruptcy petition filed against it, on July 23, 2012. The bankruptcy case is pending before the United States Bankruptcy Court for the District of Maryland. The case number for the lead bankruptcy case is 12-23557. The bankruptcy case is currently assigned to United States Bankruptcy Judge Thomas Catliota. The law firm of Greenberg Traurig, LLP is acting as lead bankruptcy counsel to Neogenix Oncology, Inc.  in the bankruptcy case.

* * * * * * * * * * * * * * * * * * * *

Chapter 11 Dockets is the most efficient, effective way to research bankruptcy cases and identify precedent.

Because it was designed by experienced restructuring professionals and is chapter 11 specific in focus, Chapter 11 Dockets is optimized for the unique needs of bankruptcy practitioners.

Learn more and sign up for a free trial by visiting

* * * * * * * * * * * * * * * * * * * *

Leave a Reply